诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

已收盘 04-18 16:00:00 EDT

92.57

-0.51

-0.55%

盘后92.57

+0.000.00%

17:48 EDT

最高92.93	最低92.35	成交量105.46万
今开92.85	昨收93.08	日振幅0.62%
总市值1,892亿	流通市值1,808亿	总股本20.44亿
成交额9,769万	换手率0.05%	流通股本19.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":92.57,"timestamp":1713470400000,"preClose":93.08,"halted":0,"volume":1054610,"hourTrading":{"tag":"盘后","latestPrice":92.57,"preClose":92.57,"latestTime":"17:48 EDT","volume":151225,"amount":13998887.26,"timestamp":1713476916132},"delay":0,"floatShares":1953000000,"shares":2044000000,"eps":7.102868,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.51,"latestTime":"04-18 16:00:00 EDT","open":92.85,"high":92.93,"low":92.35,"amount":97691482.48105,"amplitude":0.006231,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.102868,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1713513600000},"adr":1,"adjPreClose":93.08,"adrRate":1,"dividendRate":0.042335,"preHourTrading":{"tag":"盘前","latestPrice":92.82,"preClose":93.08,"latestTime":"09:29 EDT","volume":2473,"amount":229654.442668,"timestamp":1713446999999},"postHourTrading":{"tag":"盘后","latestPrice":92.57,"preClose":92.57,"latestTime":"17:48 EDT","volume":151225,"amount":13998887.26,"timestamp":1713476916132},"volumeRatio":0.634735},"requestUrl":"/m/hq/s/NVS/wiki","defaultTab":"wiki","newsList":[{"id":"2428596694","title":"可在家中自己注射 诺华制药(NVS.US)CD20靶向疗法维持高效长达6年","url":"https://stock-news.laohu8.com/highlight/detail?id=2428596694","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428596694?lang=zh_cn&edition=full","pubTime":"2024-04-18 20:59","pubTimestamp":1713445157,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月18日，诺华制药宣布其ALITHIOS开放标签扩展研究的数据，显示在新近确诊的复发性多发性硬化患者中，一线使用Kesimpta治疗可维持高效长达六年。新闻稿指出，Kesimpta是首个可通过Sensoready自动注射笔让患者在家中每月自我注射一次的B细胞靶向疗法，为患者对疾病的管理提供了便利。上述研究还发现，使用Kesimpta长达六年的治疗耐受性良好，未发现任何意外的安全信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1104891.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427918017","title":"更新版 1-英国《金融时报》称，对冲基金 Shah Capital 促成诺华董事会改组","url":"https://stock-news.laohu8.com/highlight/detail?id=2427918017","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427918017?lang=zh_cn&edition=full","pubTime":"2024-04-15 12:45","pubTimestamp":1713156303,"startTime":"0","endTime":"0","summary":"     路透社4月15日 - 据英国《金融时报》周一报道，美国对冲基金Shah Capital周一致信Novavax   董事会，要求增加两名新的独立董事。英国《金融时报》援引一封信的内容报道，Shah Capital还希望这家生物技术公司调整其Covid-19疫苗的销售策略，该疫苗基于传统疫苗技术，主要针对因辉瑞公司和Moderna公司生产的mRNA疫苗出现罕见副作用而感到不安的老年人。Shah Capital 拥有 Novavax 6.7% 的股份。Shah Capital 和 Novavax 没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427601258","title":"据英国《金融时报》报道，对冲基金 Shah Capital 因 Covid 疫苗陷入困境而敦促诺华公司调整董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2427601258","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427601258?lang=zh_cn&edition=full","pubTime":"2024-04-15 12:12","pubTimestamp":1713154379,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月15日 - 据英国《金融时报》网站 (link) 报道，美国对冲基金 Shah Capital 周一致函 Novavax 董事会，要求增加两名新的独立董事。英国《金融时报》援引一封信的内容报道，Shah Capital还希望这家生物技术公司调整其Covid-19疫苗的销售策略，该疫苗基于传统疫苗技术，主要针对那些对辉瑞和Moderna公司生产的mRNA疫苗的罕见副作用感到不安的老年人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427642927","title":"隔夜美股全复盘(4.13)| 三大股指集体收跌，中东紧张局势加剧，叠加部分美国大型银行股财报喜忧参半，美股连续第二周收跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2427642927","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2427642927?lang=zh_cn&edition=full","pubTime":"2024-04-13 07:16","pubTimestamp":1712963782,"startTime":"0","endTime":"0","summary":"三大股指集体收跌，中东紧张局势加剧，叠加部分美国大型银行股财报喜忧参半，美股连续第二周收跌","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/718741","is_publish_highlight":false,"gpt_icon":0},{"id":"2426748249","title":"诺华(NVS.US)超10亿美元囊获Arvinas潜在“best-in-class”蛋白降解剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2426748249","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426748249?lang=zh_cn&edition=full","pubTime":"2024-04-12 09:37","pubTimestamp":1712885866,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Arvinas宣布已与诺华达成独家战略许可协议。诺华将以高达10.1亿美元的款项获得Arvinas第二代雄激素受体靶向蛋白降解嵌合体ARV-766在全球范围内的开发和商业化权利。诺华同时获得Arvinas的另一款处于临床前阶段的AR靶向PROTAC降解剂AR-V7。Arvinas将获得总计1.5亿美元的预付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101492.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426253531","title":"诺华制药(NVS.US)对MorphoSys(MOR.US)发起收购要约 收购价68欧元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426253531","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426253531?lang=zh_cn&edition=full","pubTime":"2024-04-11 19:32","pubTimestamp":1712835152,"startTime":"0","endTime":"0","summary":"诺华制药已经对德国癌症制药商MorphoSys发起了收购要约，拟以每股68欧元或总计27亿欧元的现金收购该公司所有已发行股票。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240411/20240411193309_72568.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240411/20240411193309_72568.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101291.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426258783","title":"BUZZ-Arvinas 因与诺华达成前列腺癌药物许可协议而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2426258783","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426258783?lang=zh_cn&edition=full","pubTime":"2024-04-11 19:31","pubTimestamp":1712835096,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月11日 - ** 药物开发商Arvinas   股价盘前上涨3.5%至38美元** 该公司与诺华  签订了 (link) 战略许可协议，在全球范围内开发和商业化其名为 ARV-766 的前列腺癌实验药物。** 根据协议，ARVN 将获得高达 10.1 亿美元的商业里程碑以及 ARV-766 的分级特许权使用费** 交易还包括向诺华公司购买公司临床前 AR-V7 项目的资产购买协议** ARVN 将获得 1.5 亿美元的预付款，用于 ARV-766 的许可和 AR-V7 项目的销售** 截至收盘，ARVN股价年累计下跌10.8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426710851","title":"诺华将裁员约680人-36氪","url":"https://stock-news.laohu8.com/highlight/detail?id=2426710851","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2426710851?lang=zh_cn&edition=full","pubTime":"2024-04-10 07:47","pubTimestamp":1712706463,"startTime":"0","endTime":"0","summary":"诺华4月9日表示，将在其发展机构中裁减多至680个职位，该机构负责帮助公司将药物推向市场。诺华称，在未来两三年内，瑞士将裁员约440人，美国将裁员240人。（界面）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100747468b05cff2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404100747468b05cff2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426198641","title":"诺华制药(NVS)将裁员多至680人","url":"https://stock-news.laohu8.com/highlight/detail?id=2426198641","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2426198641?lang=zh_cn&edition=full","pubTime":"2024-04-09 23:06","pubTimestamp":1712675219,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药(NVS)表示，将在其发展机构中裁减多至680个职位，该机构负责帮助公司将药物推向市场。诺华称，在未来两三年内，瑞士将裁员约440人，美国将裁员240人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409230707875a7510&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409230707875a7510&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425516259","title":"诺华制药(NVS.US)：ASCVD患者早期使用Leqvio可显著降低LDL-C","url":"https://stock-news.laohu8.com/highlight/detail?id=2425516259","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2425516259?lang=zh_cn&edition=full","pubTime":"2024-04-08 16:17","pubTimestamp":1712564243,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药商诺华制药(NVS.US)一项后期临床试验的最新数据显示，早期添加其Leqvio药物可显著降低动脉粥样硬化性心血管疾病(ASCVD)患者的低密度脂蛋白胆固醇(LDL-C)。这家瑞士制药巨头周六表示，与美国通常的临床实践相比，三期试验较早地评估了加入Leqvio的有效性。该公司表示，与仅靠他汀类降胆固醇药物疗法无法实现目标的动脉粥样硬化性心血管疾病患者的常规治疗相比，早期开始使用Leqvio可以显著降低LDL-C。该公司表示，Leqvio的安全性与之前的研究一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099308.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424913187","title":"金斯瑞生物科技(01548)：传奇生物美国公司与诺华制药公司签订主要生产和供应服务协定","url":"https://stock-news.laohu8.com/highlight/detail?id=2424913187","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424913187?lang=zh_cn&edition=full","pubTime":"2024-04-01 18:37","pubTimestamp":1711967841,"startTime":"0","endTime":"0","summary":"合作伙伴将与诺华合作，促进诺华执行合同生产服务所需的资讯交换，并获得适用的执照和许可。该协定还包括诺华在执行合同生产服务时应满足的特定绩效指标。此外，合作伙伴将被要求给诺华报销用于生产产品的某些原材料的成本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1097162.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422104425","title":"尹力分别会见诺华集团、辉瑞公司、丹纳赫集团负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2422104425","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2422104425?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:32","pubTimestamp":1711373520,"startTime":"0","endTime":"0","summary":"据北京日报消息，3月25日下午，市委书记尹力分别会见了瑞士诺华集团全球首席执行官万思瀚、美国辉瑞公司董事长兼首席执行官艾伯乐和美国丹纳赫集团全球总裁兼首席执行官毕睿宁。尹力介绍了北京市经济社会发展及居民健康状况。艾伯乐表示，中国医药健康产业市场规模巨大，北京创新能力强、营商环境一流，为医药企业提供了广阔机遇，辉瑞公司愿同北京在创新研发、应对公共卫生挑战等领域进一步深化拓展合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252135467a4ee819&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403252135467a4ee819&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422456873","title":"诺华首席执行官万思瀚：加快推进放射配体疗法开发与应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2422456873","media":"北京商报","top":-1,"share":"https://www.laohu8.com/m/news/2422456873?lang=zh_cn&edition=full","pubTime":"2024-03-25 15:03","pubTimestamp":1711350186,"startTime":"0","endTime":"0","summary":"3月24-25日，中国发展高层论坛2024年年会在北京召开。诺华首席执行官万思瀚(VasNarasimhan)博士出席本次年会。在本届论坛上，诺华提交了主题为“建设有竞争力的创新生态系统，惠及中国患者”的建议，就加快放射配体疗法这一先进疗法的开发与应用积极建言。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202403253022875294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202403253022875294.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419944492","title":"诺华制药投资2.56亿美扩建新加坡厂房","url":"https://stock-news.laohu8.com/highlight/detail?id=2419944492","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2419944492?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:40","pubTimestamp":1710492000,"startTime":"0","endTime":"0","summary":"瑞士诺华制药投资2.56亿美元扩大在新加坡的生产设施，预计将在当地创造100个高技术就业职位。诺华制药的厂房在扩建后将专注于生产抗体治疗药物，公司早于2013年开始在当地投资建厂，至今投资额已超过10亿美元。(mn/a)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211229095714178_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211229095714178_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1333820/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2418396537","title":"诺华制药跌1.57% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2418396537","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418396537?lang=zh_cn&edition=full","pubTime":"2024-03-12 21:31","pubTimestamp":1710250318,"startTime":"0","endTime":"0","summary":"北京时间2024年03月12日21时31分，诺华制药股票出现异动，股价急速跳水1.57%。截至发稿，该股报99.78美元/股，成交量6.1699万股，换手率0.00%，振幅0.11%。最近的财报数据显示，该股实现营业收入454.40亿美元，净利润85.68亿美元，每股收益7.15美元，毛利328.67亿美元，市盈率14.05倍。机构评级方面，在所有26家参与评级的机构中，38%的券商给予买入建议，50%的券商给予持有建议，12%的券商给予卖出建议。诺华制药股票所在的制药行业中，整体涨幅为0.49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031221315887773aa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031221315887773aa1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2418153954","title":"德国监管机构批准诺华27亿欧元收购生物制药公司MorphoSys","url":"https://stock-news.laohu8.com/highlight/detail?id=2418153954","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2418153954?lang=zh_cn&edition=full","pubTime":"2024-03-12 20:46","pubTimestamp":1710247602,"startTime":"0","endTime":"0","summary":"德国反垄断机构联邦卡特尔局3月12日发布声明，批准瑞士制药巨头诺华收购德国生物技术公司MorphoSys的交易。2月5日，诺华宣布将以每股68欧元或总计27亿欧元现金收购MorphoSys。此次收购需满足惯例成交条件，包括收购要约中最低65%流通股的接受门槛以及监管部门的批准。根据声明，此次收购将进一步扩展和补充诺华在肿瘤学这一优先治疗领域的产品线，同时将加强诺华在血液学领域的全球布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403122046427919b87a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403122046427919b87a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417050903","title":"诺华制药涨0.06% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2417050903","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417050903?lang=zh_cn&edition=full","pubTime":"2024-03-08 22:31","pubTimestamp":1709908283,"startTime":"0","endTime":"0","summary":"北京时间2024年03月08日22时31分，诺华制药股票出现波动，股价急速上涨0.06%。截至发稿，该股报99.99美元/股，成交量2.5701万股，换手率0.00%，振幅0.05%。最近的财报数据显示，该股实现营业收入454.40亿美元，净利润85.68亿美元，每股收益7.15美元，毛利328.67亿美元，市盈率14.08倍。诺华制药股票所在的制药行业中，整体跌幅为0.56%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403082231238765c9e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403082231238765c9e8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411544788","title":"诺华制药涨0.99% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2411544788","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411544788?lang=zh_cn&edition=full","pubTime":"2024-02-15 23:01","pubTimestamp":1708009308,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日23时01分，诺华制药股票出现波动，股价快速拉升0.99%。截至发稿，该股报100.03美元/股，成交量11.3719万股，换手率0.01%，振幅0.68%。诺华制药股票所在的制药行业中，整体涨幅为0.43%。其相关个股中，Cardiol Therapeutics Inc、Organon & Co、Clever Leaves Holdings Inc C/Wts 18/12/2025涨幅较大，苏轩堂、Sunshine Biopharma Inc、Petros Pharmaceuticals Inc较为活跃，换手率分别为18.60%、11.74%、11.45%，振幅较大的相关个股有Cardiol Therapeutics Inc、惠普森医药、Durect Corp，振幅分别为18.99%、12.74%、12.69%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215230148861d55f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215230148861d55f3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411818945","title":"BUZZ-Erasca 因与诺华开展试验和供应合作而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2411818945","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411818945?lang=zh_cn&edition=full","pubTime":"2024-02-15 01:00","pubTimestamp":1707930054,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    2月14日 - ** 癌症药物开发商Erasca  股价上涨3.3%至1.72美元 ** 公司宣布 (link) 与诺华  签订新的合作和供应协议 ** 这些协议将支持早期和晚期试验，测试ERAS的试验性药物naporafenib与NOVN的批准药物Mekinist联用的情况。** Co赞助试验，NOVN免费提供Mekinist** ERAS预计在24年上半年报告最后阶段研究结果，在2024年第二季度至第四季度报告早期研究结果 ** 过去12个月股价下跌57.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0296},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.0169},{"period":"1year","weight":-0.0436},{"period":"ytd","weight":-0.0781}],"compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":-0.024},{"period":"3month","weight":0.0505},{"period":"6month","weight":0.1884},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0531}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日在瑞士成立。该公司提供满足全球患者和社会不断变化的需求的医疗保健解决方案。他们广泛的产品组合包括创新药物和肿瘤药物，仿制药和生物仿制药以及眼科护理设备。他们的使命是发现改善和延伸人们生活的新方法。他们的愿景是成为改变医学实践的值得信赖的领导者。他们的战略是利用科学的创新在不断增长的医疗领域提供更好的患者结果。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.014981},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.012188},{"month":3,"riseRate":0.5,"avgChangeRate":0.000575},{"month":4,"riseRate":0.666667,"avgChangeRate":0.017001},{"month":5,"riseRate":0.652174,"avgChangeRate":0.006502},{"month":6,"riseRate":0.541667,"avgChangeRate":0.009763},{"month":7,"riseRate":0.708333,"avgChangeRate":0.012897},{"month":8,"riseRate":0.375,"avgChangeRate":-0.006962},{"month":9,"riseRate":0.708333,"avgChangeRate":0.011946},{"month":10,"riseRate":0.458333,"avgChangeRate":-0.010373},{"month":11,"riseRate":0.625,"avgChangeRate":0.016564},{"month":12,"riseRate":0.708333,"avgChangeRate":0.0233}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}